Injectable supramolecular hydrogel shows promise for neoadjuvant immunotherapy of triple-negative breast cancer

Injectable supramolecular hydrogel shows promise for neoadjuvant immunotherapy of triple-negative breast cancer

The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of cytotoxic T lymphocytes (CTLs). Although neoadjuvant chemotherapy together with immunotherapy has been approved for advanced TNBC, its efficacy is still unsatisfactory, possibly due to systemic treatment-induced lymphatic system disorders and upregulation of additional immune checkpoints in the tumors.

​Medical Xpress – latest medical and health news stories

Read More


Discover more from Nurse Unity Chats

Subscribe to get the latest posts sent to your email.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *